AbbVie looks to shed Allergan's legacy women's health unit as it hunkers down for Humira biosim doomsday — report
With the clock ticking on its blockbuster Humira patent in the US, AbbVie is reportedly in talks to sell the $5 billion women’s health portfolio …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
